August 25, 2016 5:01pm

… Big drop at 2 p.m. as sellers and buyers catch “conflicting tendency” fever

Speculation fuels the tape as Friday’s “economic event” and the summer weekend approach

 

 … I wholehearted believe, “our” universe’s pricing is ripening for an uptick for the oversold

 

Pre-open indication’s tally:  1 hit (OPXA) and 4 miss (AGTC, BLUE, CLLS and XON)

Financial results/earnings: QURE

 

I answer one question; in which company should investors put, keep and commit their money!

 

Do you care what happened today, you should … because it has implications to Friday's sector activity?   Where has today’s market gone – subscribe and find out. 

 


 

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

 

U.S. equities closed lower Thursday, with health care falling approximately 1 percent, a day ahead of a key speech from the Fed’s Chair Yellen.

The NASDAQ closed DOWN -5.49 or -0.11% to 5,212.20 and the DOW closed DOWN -33.07 or -0.18% to 18,448.41.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:    

  • The open was neutral with an A/DL of 21/21 and 1 flat;
  • The mid-day was barely positive  with an A/DL of 21/20 and 2 flats;
  • The closing bell was negative with A/DL of 13/29 and 1 flat;

 

 

Henry’omics:

The stem, cell, gene and regenerative therapy (SCGT&RT) sector was neutral at the opening bell, barely positive at the mid-day as the sector took a BIG hit at the 2 p.m. timeframe with the sector closing negative.

  • Volume has dropped off due to the many vacationing investors.

I am sticking to my thesis;  stem, cell, gene and regenerative therapy stocks “danced” all over the tape in my mind opening the door to a solid pricing spurt!

  • I’m still holding on to “some” equities, recommending BUYING the oversold while sticking my head in the sand until after Labor Day!

 

Call me cantankerous, contrarian or even a curmudgeon but at the least I get it right and investors make money!

 

 

Today’s Bottom Line:

The word of the day, “ouch”, be prepared for a better day … probably starting Monday

 

 

Financial results/earnings;

UniQure NV (QURE) reported a Q2 loss of $21.3 M or -$0.98 per share.

  • The results fell short of expectations. The average estimate was for a loss of $0.87 per share.
  • QURE posted revenue of $1.8 M, also missing street forecasts having expected $4.1 M.
  • UniQure shares have declined 50% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $8.23, a decline of 65% in the last 12 months.
  • QURE end Q2 with $186.6 M

 

 

Pre-open indication’s tally:  1 hit and 4 miss:

  • Applied Genetic Technologies (AGTC) closed DOWN -$0.28 – miss;
  • bluebird bio (BLUE) closed DOWN -$0.29 – miss;
  • Cellectis SA (CLLS) closed DOWN -$0.51 – miss;
  • Intrexon (XON) closed DOWN -$0.61 – miss;
  • Opexa (OPXA) closed DOWN -$0.14 – hit;

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Thursday traded near 14;
  • Wednesday traded 13.39;
  • Tuesday traded 12.19;
  • Monday traded 12.6;
  • Friday traded near 11.6;
  • Last Thursday trade near 11.6;

 

 

Decliners:

  • Adverum (ADVM) -9.14%;
  • Fate Therapeutics (FATE) -6.14%;
  • Aduro Biotech (ADRO) -5.43%;
  • Neuralstem (CUR) -5.31%;
  • Opexa (OPXA) -4.87%;
  • Vericel (VCEL -4.74%

 

Advancers:

  • VistaGen (VTGN) +1.25%;
  • Pluristem (PSTI) +2.96% after Wednesday’s +0.60% - be ready for the “drip”;
  • Organovo (ONVO) +2.63%;
  • Stemline (STML) +2.37% after Wednesday’s +4.03%;
  • Verastem (VSTM) +2.21%;
  • Mesoblast (MESO) +2.61% after Wednesday’s -10.59% - as I had stated an opportunity;

 

Flat:

  • ReNeuron (RENE.L ) at $2.75

                                                                                                                                       

                                                                                                  

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.